within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J07A_BacterialVaccines.J07AC01_AnthraxAntigen;

model AnthraxAntigen
  extends Pharmacolibrary.Drugs.ATC.J.J07AC01;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>J07AC01</td></tr><td>route:</td><td>intramuscular</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Anthrax antigen (protective antigen, PA) is the principal immunogenic component of anthrax vaccines used for the prevention of Bacillus anthracis infection (anthrax) in humans. Vaccines containing anthrax antigen are used particularly in high-risk populations, such as military personnel or persons with occupational exposure. Licensed anthrax vaccines (e.g., Anthrax Vaccine Adsorbed, AVA) are approved by regulatory agencies for prophylactic use.</p><h4>Pharmacokinetics</h4><p>No peer-reviewed population pharmacokinetic studies for the anthrax antigen (protective antigen, PA) in healthy adults, children, elderly, or specific patient groups were identified. Pharmacokinetic estimates below are based on general knowledge of subcutaneous or intramuscular administration of protein antigen vaccines.</p><h4>References</h4><ol><li><p>Nagy, CF, et al., &amp; Guttendorf, R (2018). Safety, Pharmacokinetics, and Immunogenicity of Obiltoxaximab After Intramuscular Administration to Healthy Humans. <i>Clinical pharmacology in drug development</i> 7(6) 652–660. DOI:<a href=\"https://doi.org/10.1002/cpdd.410\">10.1002/cpdd.410</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29125719/\">https://pubmed.ncbi.nlm.nih.gov/29125719</a></p></li><li><p>Mohamed, N, et al., &amp; Casey, L (2005). A high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge. <i>Infection and immunity</i> 73(2) 795–802. DOI:<a href=\"https://doi.org/10.1128/IAI.73.2.795-802.2005\">10.1128/IAI.73.2.795-802.2005</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/15664918/\">https://pubmed.ncbi.nlm.nih.gov/15664918</a></p></li><li><p>Riddle, V, et al., &amp; Lowy, I (2011). Phase I study evaluating the safety and pharmacokinetics of MDX-1303, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers. <i>Clinical and vaccine immunology : CVI</i> 18(12) 2136–2142. DOI:<a href=\"https://doi.org/10.1128/CVI.05059-11\">10.1128/CVI.05059-11</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/21976227/\">https://pubmed.ncbi.nlm.nih.gov/21976227</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end AnthraxAntigen;
